Todd Davis: Expending Portfolio and Setting ambitious growth targets
Todd Davis, CEO at Ligand Pharmaceuticals, shared on LinkedIn:
“On the Ligand Pharmaceuticals earnings call this week, I highlighted the steps we have taken to transform the company over the past 18 months and strengthen and expand our royalty portfolio and team. I am pleased to report that during the first half of 2024, we committed $175 million to two new investment opportunities. One of these transactions was the acquisition of APEIRON Biologics, a $100 million investment, and one of our most recent commitments of capital across our platform.
We also added four commercial-stage products to our portfolio and expanded the bench strength of our investment, business development, and operational teams with several new hires.
I am proud of our tremendous progress during the first half of 2024. We have set ambitious yet realistic targets for long-term growth and believe we are well-positioned to create further value for our shareholders.”
Source: Todd Davis/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023